<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ichicsr SYSTEM "ich-icsr-v2.1.dtd">
<ichicsr lang="en">
  <ichicsrmessageheader>
    <messagetype>ichicsr</messagetype>
    <messageformatversion>2.1</messageformatversion>
    <messageformatrelease>1.0</messageformatrelease>
    <messagenumb>2022-04</messagenumb>
    <messagesenderidentifier>FDA CDER</messagesenderidentifier>
    <messagereceiveridentifier>Public Use</messagereceiveridentifier>
    <messagedateformat>204</messagedateformat>
    <messagedate>20220424074800</messagedate>
  </ichicsrmessageheader>
  <safetyreport>
    <safetyreportversion>3</safetyreportversion>
    <safetyreportid>19454107</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220425</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20210623</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220104</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-KYOWAKIRIN-2021BKK010344</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Constipation</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Decreased appetite</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>NOURIANZ</medicinalproduct>
        <drugbatchnumb>CDNCX</drugbatchnumb>
        <drugauthorizationnumb>22075</drugauthorizationnumb>
        <drugstructuredosagenumb>20</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>20 MG, ONE TABLET ONCE DAILY</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Parkinson^s disease</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20201113</drugstartdate>
        <actiondrug>4</actiondrug>
        <activesubstance>
          <activesubstancename>ISTRADEFYLLINE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20270107</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220425</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>1</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220101</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220101</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-PURDUE-USA-2020-0256501</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Overdose</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug dependence</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug withdrawal syndrome</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Emotional distress</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OXYCONTIN</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugauthorizationnumb>022272</drugauthorizationnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OXYCODONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DILAUDID</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>HYDROMORPHONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>MS CONTIN</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>MORPHINE SULFATE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20300948</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>1</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>1</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220105</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220105</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-PURDUE-USA-2020-0252288</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Overdose</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug dependence</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Drug withdrawal syndrome</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Pain</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Emotional distress</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>OXYCONTIN</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugauthorizationnumb>022272</drugauthorizationnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>OXYCODONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DILAUDID</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>HYDROMORPHONE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>MS CONTIN</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugdosageform>Prolonged-release tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>MORPHINE SULFATE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>DEMEROL</medicinalproduct>
        <drugbatchnumb>Unknown</drugbatchnumb>
        <drugdosagetext>UNKNOWN</drugdosagetext>
        <drugadministrationroute>065</drugadministrationroute>
        <drugindication>Product used for unknown indication</drugindication>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>MEPERIDINE HYDROCHLORIDE</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>5</safetyreportversion>
    <safetyreportid>19264942</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>2</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20210517</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220131</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>NVSC2021US108270</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>5</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Arthralgia</reactionmeddrapt>
        <reactionoutcome>3</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>COSENTYX</medicinalproduct>
        <drugbatchnumb>not available</drugbatchnumb>
        <drugauthorizationnumb>125504</drugauthorizationnumb>
        <drugstructuredosagenumb>300</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>802</drugintervaldosagedefinition>
        <drugdosagetext>UNK UNK, QW</drugdosagetext>
        <drugdosageform>Solution for injection</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>Psoriatic arthropathy</drugindication>
        <drugstartdateformat>102</drugstartdateformat>
        <drugstartdate>20210504</drugstartdate>
        <actiondrug>4</actiondrug>
        <activesubstance>
          <activesubstancename>SECUKINUMAB</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>COSENTYX</medicinalproduct>
        <drugauthorizationnumb>125504</drugauthorizationnumb>
        <drugdosagetext>UNK</drugdosagetext>
        <drugdosageform>Solution for injection</drugdosageform>
        <drugadministrationroute>065</drugadministrationroute>
        <actiondrug>4</actiondrug>
        <activesubstance>
          <activesubstancename>SECUKINUMAB</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20395365</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>1</serious>
    <seriousnessdeath>1</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220130</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220130</receiptdate>
    <fulfillexpeditecriteria>1</fulfillexpeditecriteria>
    <companynumb>US-NOVARTISPH-NVSC2022US020023</companynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>4</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>41</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Colorectal cancer</reactionmeddrapt>
        <reactionoutcome>5</reactionoutcome>
      </reaction>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Incorrect dose administered</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RANITIDINE</medicinalproduct>
        <drugauthorizationnumb>74467</drugauthorizationnumb>
        <drugstructuredosagenumb>150</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>25 MG,75 MG,150 MG,,DAILY,</drugdosagetext>
        <drugdosageform>Tablet</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>201001</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>201512</drugenddate>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RANITIDINE</medicinalproduct>
        <drugauthorizationnumb>74467</drugauthorizationnumb>
        <drugdosageform>Tablet</drugdosageform>
        <drugindication>Dyspepsia</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RANITIDINE</medicinalproduct>
        <drugauthorizationnumb>74467</drugauthorizationnumb>
        <drugdosageform>Tablet</drugdosageform>
        <drugindication>Gastrooesophageal reflux disease</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RANITIDINE</medicinalproduct>
        <drugstructuredosagenumb>150</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>25 MG,75 MG,150 MG,,DAILY,</drugdosagetext>
        <drugdosageform>Capsule, hard</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>201001</drugstartdate>
        <drugenddateformat>610</drugenddateformat>
        <drugenddate>201512</drugenddate>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RANITIDINE</medicinalproduct>
        <drugdosageform>Capsule, hard</drugdosageform>
        <drugindication>Dyspepsia</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE</activesubstancename>
        </activesubstance>
      </drug>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>RANITIDINE</medicinalproduct>
        <drugdosageform>Capsule, hard</drugdosageform>
        <drugindication>Gastrooesophageal reflux disease</drugindication>
        <actiondrug>6</actiondrug>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>RANITIDINE</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20150101</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20345305</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <occurcountry>US</occurcountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <receivedateformat>102</receivedateformat>
    <receivedate>20220118</receivedate>
    <receiptdateformat>102</receiptdateformat>
    <receiptdate>20220118</receiptdate>
    <fulfillexpeditecriteria>2</fulfillexpeditecriteria>
    <companynumb>US-CELGENE-USA-20220103809</companynumb>
    <duplicate>1</duplicate>
    <reportduplicate>
      <duplicatesource>Optum Specialty Pharmacy</duplicatesource>
      <duplicatenumb>AE00542964</duplicatenumb>
    </reportduplicate>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>2</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>80</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientsex>1</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Nasopharyngitis</reactionmeddrapt>
        <reactionoutcome>6</reactionoutcome>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>REVLIMID</medicinalproduct>
        <drugbatchnumb>UNKNOWN</drugbatchnumb>
        <drugauthorizationnumb>021880</drugauthorizationnumb>
        <drugstructuredosagenumb>10</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>804</drugintervaldosagedefinition>
        <drugdosagetext>10 MILLIGRAM</drugdosagetext>
        <drugdosageform>Capsules</drugdosageform>
        <drugadministrationroute>048</drugadministrationroute>
        <drugindication>Plasma cell myeloma</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>202103</drugstartdate>
        <actiondrug>5</actiondrug>
        <drugrecurreadministration>3</drugrecurreadministration>
        <drugadditional>3</drugadditional>
        <activesubstance>
          <activesubstancename>LENALIDOMIDE</activesubstancename>
        </activesubstance>
      </drug>
      <summary>
        <narrativeincludeclinical>CASE EVENT DATE: 20220112</narrativeincludeclinical>
      </summary>
    </patient>
  </safetyreport>
  <safetyreport>
    <safetyreportversion>1</safetyreportversion>
    <safetyreportid>20368848</safetyreportid>
    <primarysourcecountry>US</primarysourcecountry>
    <transmissiondateformat>102</transmissiondateformat>
    <transmissiondate>20220423</transmissiondate>
    <reporttype>1</reporttype>
    <serious>2</serious>
    <seriousnessdeath>2</seriousnessdeath>
    <seriousnesslifethreatening>2</seriousnesslifethreatening>
    <seriousnesshospitalization>2</seriousnesshospitalization>
    <seriousnessdisabling>2</seriousnessdisabling>
    <seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
    <seriousnessother>2</seriousnessother>
    <receivedate>20220121</receivedate>
    <receiptdate>20220121</receiptdate>
    <fulfillexpeditecriteria>3</fulfillexpeditecriteria>
    <authoritynumb>FDA-CDER-CTU-2022-5908</authoritynumb>
    <primarysource>
      <reportercountry>US</reportercountry>
      <qualification>3</qualification>
    </primarysource>
    <sender>
      <sendertype>2</sendertype>
      <senderorganization>FDA-Public Use</senderorganization>
    </sender>
    <receiver>
      <receivertype>6</receivertype>
      <receiverorganization>FDA</receiverorganization>
    </receiver>
    <patient>
      <patientonsetage>57</patientonsetage>
      <patientonsetageunit>801</patientonsetageunit>
      <patientweight>117.03</patientweight>
      <patientsex>2</patientsex>
      <reaction>
        <reactionmeddraversionpt>24.1</reactionmeddraversionpt>
        <reactionmeddrapt>Nasopharyngitis</reactionmeddrapt>
      </reaction>
      <drug>
        <drugcharacterization>1</drugcharacterization>
        <medicinalproduct>HUMIRA</medicinalproduct>
        <drugbatchnumb>1155481</drugbatchnumb>
        <drugstructuredosagenumb>40</drugstructuredosagenumb>
        <drugstructuredosageunit>003</drugstructuredosageunit>
        <drugseparatedosagenumb>1</drugseparatedosagenumb>
        <drugintervaldosageunitnumb>2</drugintervaldosageunitnumb>
        <drugintervaldosagedefinition>803</drugintervaldosagedefinition>
        <drugdosagetext>FREQUENCY : EVERY OTHER WEEK;?</drugdosagetext>
        <drugdosageform>Injection</drugdosageform>
        <drugadministrationroute>058</drugadministrationroute>
        <drugindication>Rheumatoid arthritis</drugindication>
        <drugstartdateformat>610</drugstartdateformat>
        <drugstartdate>202101</drugstartdate>
        <drugadditional>4</drugadditional>
        <activesubstance>
          <activesubstancename>ADALIMUMAB</activesubstancename>
        </activesubstance>
      </drug>
    </patient>
  </safetyreport>
</ichicsr>
